Table 6.
Comparison of edema attacks and AECT scores before and after lanadelumab treatment
| No. of patients | HAE type | Attacks in 3 months | AECT scores | ||
|---|---|---|---|---|---|
| Base-line | Post-treatment | Base-line | Post-treatment | ||
| 1 | HAE-1 | 9 | 0 | 2 | 12 |
| 2 | 2 | 0 | 4 | 13 | |
| 3 | 12 | 1 | 1 | 12 | |
| 4 | 4 | 0 | 3 | 13 | |
| 5 | 3 | 0 | 3 | 13 | |
| 6 | 2 | 0 | 2 | 13 | |
| 7 | HAE-2 | 2 | 0 | 1 | 14 |
| 8 | HAE-nC1-INH | 5 | 3 | 2 | 8 |
| Mean ± SD/Median (IQR) | 3.5 (2,8) | 0 (0,0.75) | 2.25 ± 1.04 | 13 (12,13) | |
| p | < 0.001 | < 0.001 | |||
*AECT refers to the Angioedema Control Test, with a score of 10 or higher indicating good control. Normality of the sample distribution was assessed using the Shapiro-Wilk test. The p-value for comparison of edema attacks was obtained using the Mann-Whitney U test, while the p-value for comparing AECT scores was derived from an independent samples t-test
*The patient with “HAE-FXII” was also treated with lanadelumab but is not listed in this table because her swelling was persistent and cannot made a before-and-after comparison on the number of episodes and the AECT score